New market study, "Switzerland Pharmaceuticals & Healthcare Report Q1 2016", has been published

Roche's restructuring efforts within its manufacturing network are indicative of deep pipeline shifts. Tailored manufacturing capability will support the company's established biosimilar defence strategy as it prepares itself for erosion of key product revenues to begin in 2018. As part of an industry-wide trend, we expect to see further traditional small-molecule plants being decommissioned and investment being put into increasing in-house biologics capabilities.

Headline Expenditure Projections

Pharmaceuticals: CHF7.06bn (USD7.71bn) in 2014 to CHF7.07bn (USD7.27bn) in 2015; +0.10% in local currency terms and -5.8% in US dollar terms. Forecast stayed flat compared to last quarter.
Healthcare: CHF70.49bn (USD77.02bn) in 2014 to CHF71.88bn (USD73.89bn) in 2015; +2.0% growth in local currency terms and -4.1% in US dollar terms. Forecast revised slightly downwards from last quarter.

Risk/Reward Index

High per-capita spending on medicines as well as a growing demand for medicines as a result of the country's ageing population makes Switzerland an attractive market in which to launch innovative medicines. However, the government's focus on cost containment within the pharmaceuticals and healthcare sector will continue to pose challenges to drug companies.

Full Report Details at
- http://www.fastmr.com/prod/1109825_switzerland_pharmaceuticals.aspx?afid=301

The Switzerland Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Switzerland Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Switzerland pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's pharmaceutical and healthcare market forecasts for Switzerland, to test other views - a key input for successful budgeting and strategic business planning in the Swiss pharmaceutical and healthcare market.
* Target business opportunities and risks in the Swiss pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Switzerland.
* Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View



About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- France Pharmaceuticals & Healthcare Report Q1 2016
- Saudi Arabia Pharmaceuticals & Healthcare Report Q1 2016
- Kenya Pharmaceuticals & Healthcare Report Q1 2016
- Ukraine Pharmaceuticals & Healthcare Report Q1 2016
- Thailand Pharmaceuticals & Healthcare Report Q1 2016